All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the ASCO 2022 Annual Meeting, the MPN Hub was pleased to speak to Ruben Mesa, UT Health San Antonio, San Antonio, US. We asked, How might momelotinib change the treatment for cytopenic patients with MF?
MOMENTUM: How might momelotinib change the treatment for cytopenic patients with MF?
Mesa begins by discussing data presented at ASCO 2022 from the MOMENTUM study, and the mechanism of action of momelotinib. Mesa talks about the primary endpoints of the study, and the reduction in splenomegaly symptoms and anemia.
Novel agents to treat MF with suboptimal response to ruxolitinib: Long-term outcome with momelotinib
Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway dysregulation is central to the pathogenesis of myelofibrosis...
Review of novel agents for myeloproliferative neoplasms
In the last 15 years, there have been rapid advances in understanding the importance and therapeutic potential of the Janus kinase/signal transducers and activators of transcription (JAK/STAT)...
Subscribe to get the best content related to MPN delivered to your inbox